



# Iowa Department of Human Services

Terry E. Branstad  
Governor

Kim Reynolds  
Lt. Governor

Charles M. Palmer  
Director

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

June 4, 2014

**Location: Learning Resource Center  
Fairmeadows Room  
3550 Mills Civic Parkway  
West Des Moines, Iowa**

**Time: 9:30 a.m. – 1:30 p.m.**

### Tentative Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the Minutes
2. Commission Business – Updated Business Associate Agreement (BAA)
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Review of Medical Necessity
  - a) Naloxone Rescue
8. Focus Studies/Provider Education Initiatives
  - a) Zolpidem 10mg Dose in Females – Follow Up
  - b) Zolpidem 12.5mg Dose in Females – Follow Up
  - c) Duplicate SSRIs – Follow Up
  - d) Duplicate TCAs – Follow Up
  - e) Duplicate Antidepressants – Two or More Concurrently – Follow Up
  - f) Duplicate Antidepressants - MAO Inhibitor plus SSRI or TCA – Follow Up
  - g) Prescriber Trends in Opiate Prescribing – Follow-up
  - h) Long Term Use of Short-Acting Opioids – Updated
  - i) Naltrexone use in Children – Initial Review
  - j) Adalimumab use without Methotrexate – Initial Review

9. Public Comment (See Conflict of Interest Disclosure Form)

10. Prior Authorization

- a) Chronic Pain Syndromes – Initial Review
- b) Omalizumab (Xolair<sup>®</sup>) – Initial Review
- c) Apixaban (Eliquis<sup>®</sup>) – Initial Review
- d) Dabigatran (Pradaxa<sup>®</sup>) – Initial Review
- e) Hepatitis C Protease Inhibitors – Second Review
- f) Antidepressants – Second Review
- g) Ivacaftor (Kalydeco<sup>®</sup>) – Second Review

11. Miscellaneous

- a) DUR Digest Vol. 26, No. 3 – Second Review
- b) MedWatch

12. Executive Closed Session

- a) Approval of Minutes
- b) Member Profiles

13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**\*\*\*Next Meeting August 6, 2014\*\*\*  
At the West Des Moines Learning Resource Center  
3550 Mills Civic Parkway, West Des Moines**